To determine whether SAMHD1 levels influence DLBCL response to PARP inhibitors, we examined cellular sensitivity to Veliparib in RCK-8, RIVA, SUDHL-4 and SUDHL-6 cell lines with lower and higher SAMHD1 levels, as shown above. The gene discussed is SAMHD1; the disease is diffuse large B-cell lymphoma.